Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
OTC Dry Eye Drops Market Size
The global OTC dry eye drops market size was valued at USD 1.75 billion in 2024. The market is anticipated to grow from USD 1.85 billion in 2025 to USD 3.1 billion in 2034, growing at a CAGR of 5.8% from 2025 to 2034. The market is experiencing significant growth, primarily as a result of the increasing global prevalence of dry eye syndrome across different age demographics.
To get key market trends
For example, as per the American Academy of Ophthalmology, approximately 20 million people in the U.S. and around 344 million people worldwide have dry eye disease (DED), and that number is growing in both young and old adults. Increased usage of smartphones, tablets, and computer screens has led to the exacerbation of dry eye symptoms, especially in the younger and middle-aged groups. Several environmental factors such as pollution, dust, long hours in air conditioning, and prolonged usage of digital devices disrupt the natural tear film, resulting in the higher demand for OTC dry eye drops.
OTC Dry Eye Drops Market Report Attributes
Report Attribute
Details
Base Year:
2024
OTC Dry Eye Drops Market size in 2024:
USD 1.8 Billion
Forecast Period:
2025 - 2034
Forecast Period 2023 - 2032 CAGR:
5.8
2023 Value Projection:
USD 3.1 Billion
Historical Data for:
2021 - 2024
No of Pages:
131
Tables, Charts & Figures:
145
Segments Covered:
Product Type, Type, Viscosity, Distribution Channel, and Region
Growth Drivers:
Rising prevalence of dry eye syndrome
Growing awareness and self-care practices
Increased screen time and digital device usage
Technological advancements in product formulations
Pitfalls Challenges:
Side effects and allergic reactions
Availability of alternative treatments
What are the growth opportunities in this market?
Additionally, the market is benefitting from the growing self-care and preventative health trends. Nowadays, consumers prefer to use OTC products, like eye drops, to self-manage health issues, such as eye dryness, before seeing a healthcare provider. Enhanced self-health assessment alongside heightened awareness of health problems among users facilitates self-diagnosis and treatment of dry eye disease (DED) with over the counter (OTC) drugs. The trend is further supported by retail pharmacy chains and e-commerce sites, increasing the availability of OTC eye care products.
Furthermore, growth of the OTC dry eye drops market is driven by innovation in product formulation and packaging. There is a growing focus among manufacturers on ease-of-use items like preservative-free pourable gel drops, screw-cap bottles, and multi-dose vials that have longer shelf lives. These advancements improve safety and user experience; thus, attracting more users to OTC dry eye drops. Effective advertising is also being used by these firms to inform the public and enhance the visibility of the products at all sales outlets, thus further increasing the adoption of OTC dry eye drops.
OTC dry eye drops are over-the-counter, non-prescription eye lubricants designed to alleviate dry eye symptoms such as irritation, burning, or a rough, gritty feeling in the eyes. Also commonly known as artificial tears, these eye drops can easily be obtained off the shelf and are intended to replace tears as needed.
OTC Dry Eye Drops Market Trends
The growth of the market is substantially driven by the rising aging population. The production of tears generally slows down with age, increasing the risk of dry eye syndrome.
As per studies, the prevalence estimates of dry eye disease (DED) vary widely worldwide, ranging from 5% to 87.5% in the general population, but in elderly populations (over 60 years), prevalence rates are notably higher.
Similarly, among individuals aged 18–34 years, the prevalence of severe dry eye is relatively low at 2.7%. However, in those aged above 34 years, the rate sharply rises to 18.6%, underscoring the role of aging in tear film instability and ocular surface degeneration. This age-related trend of increasing severity of dry eyes with increasing age highlights the expanding demand for effective and accessible OTC dry eye solutions, especially among older adults.
Moreover, older adults also have higher chances of having some health issues or taking medications that worsen dry eye symptoms, such as antihistamines, beta-blockers, and diuretics. Thus, the rapidly rising geriatric population, especially in developed and emerging countries, fosters the need for easily available OTC dry eye drops. These solutions are easily accessible and inexpensive, serving as the initial treatment option for chronic eye discomfort in seniors.
In addition, a sharp increase in screen time and digital device usage has resulted in higher demand for OTC dry eye drops. People use smartphones, computers, and tablets for recreational activities, work, or education, which leads to eye strain and dryness because of reduced blinking and prolonged durations of staring at screens.
Recent studies demonstrate the link between digital device usage and the rising prevalence of dry eye symptoms. According to the Vision Council, at least 60% of American men and 65% of American women reported symptoms of digital eye strain. Of these, about 80% of adults use digital devices for at least 2 hours daily, and more than 65% of adults use at least 2 devices simultaneously. Around 80% of adults use digital devices just before sleep and at least 70% of adults report that their children have a screen exposure time of at least 2 hours.
Furthermore, a study published in BMC Ophthalmology found that individuals who spend more than four hours daily on screens are significantly more likely to develop dry eye disease.
These statistics draw attention to rising public concern and are in direct correspondence with the increased need for over-the-counter dry eye drops which provide easy and cost-effective relief.
Trump Administration Tariffs
The tariffs implemented by the Trump administration, especially those concerning imports from China, might significantly impact various healthcare sectors including the OTC dry eye drops market. According to recent data from the White House, while pharmaceuticals received an exemption from the initial reciprocal tariffs announced in April 2025, President Trump has indicated that pharmaceutical-specific tariffs might still be forthcoming. This potential policy shift could affect the market.
Several dry eye drop products may depend on raw materials, packaging components, or even fully manufactured goods from China and other countries potentially affected by tariffs. With potentially increased import costs due to tariffs, manufacturers might experience higher production expenses that could result in elevated wholesale and retail prices.
Most adversely impacted might be smaller companies with less flexible supply chains, who could face difficult choices between reducing profit margins or passing costs directly to consumers.
In some instances, these pricing dynamics might cause temporary shortages or force manufacturers to switch to different suppliers, potentially complicating supply chain logistics and regulatory approval processes.
For consumers, these potential cost increases could mean reduced access or longer waits to afford OTC dry eye treatments. This might particularly affect the estimated 6.8% of the U.S. adult population diagnosed with dry eye disorder (DED), according to the National Health and Wellness Survey. The retail pharmacies segment might see pricing pressures that could affect consumer purchasing behaviors.
The overall trade tensions could potentially result in reduced investment and innovation in the eye care industry.
Overall, the Trump-era tariffs might complexly impact the market for OTC dry eye drops by potentially increasing costs of basic resources, fragmenting supply chains, and adding uncertainty, all of which could affect both manufacturers and consumers. The fact that pharmaceuticals received a temporary exemption from the initial round of tariffs suggests the administration recognizes the sector's importance, but President Trump's April 2025 comments about future pharmaceutical-specific tariffs indicate that the industry should prepare for possible trade policy changes.
OTC Dry Eye Drops Market Analysis
Learn more about the key segments shaping this market
Based on the product type, the global market is segmented into preservative and preservative-free. The preservative segment accounted for the highest market share and was valued at USD 989.3 million in 2024.
The preservative-containing dry eye drops command a significant share in the market due to their ease of access, low cost, and proven effectiveness.
Preservatives like benzalkonium chloride (BAK) are routinely employed to prevent microbial contamination in multi-use bottles because their use extends product shelf-life and decreases the need for refrigeration.
This has resulted in preservative-containing eye drops becoming a standard choice for dry eye patients seeking inexpensive and easily available remedies at retail pharmacies and online.
Another factor that supports the segment's dominance is brand recognition, familiarity, and trust. Leading OTC brands are still issuing preservative-based formulations which have been on sale for decades, ensuring a loyal customer base.
Moreover, the inclusion of preservatives permits the production of compact, easy-to-carry, multi-dose containers which improve user convenience, further enhancing reliance on these products over more expensive preservative-free alternatives.
Learn more about the key segments shaping this market
Based on the type, the global OTC dry eye drops market is categorized into branded and generics. The branded segment dominated the market with 63.4% market share in 2024.
The branded segment holds a substantial share of the market in market because of brand name recognition and consumer loyalty.
Well-known pharmaceutical companies such as Allergan (Refresh), Bausch + Lomb (Soothe), and Alcon (Systane) benefit from years of clinical credibility, advertising, and physician recommendations.
Patients suffering from moderate to chronic dry eyes tend to prefer branded products due to the perception that they are more effective and safer, regardless of the higher cost relative to generics.
In addition, branded OTC eye drops frequently have a wider variety of products designed for specific needs like preservative-free, severe dryness, or contact lens-friendly versions. These differentiated offerings help capture a wide range of customers and create loyalty among users.
Based on the viscosity, the global OTC dry eye drops market is categorized into low viscosity and high viscosity. The low viscosity segment dominated the market in 2024 and is anticipated to witness growth at a CAGR of 5.5%.
The low viscosity segment maintains a dominant position in the market, as these eye drops provide instant and effortless relief from mild to moderate dry eye symptoms.
Low viscosity formulations are mainly water-based and provide immediate hydration without significant blurring of vision. This is crucial for people who need to apply the liquid frequently during activities such as reading, driving, or using a computer, as it enables unhindered vision.
These products are generally water-based and have a lower thickness that allows users to apply the product without worrying about visual blurriness or stickiness post-application. Their lightweight consistency enables effortless application to the ocular surface, thus promoting a soothing effect while minimizing discomfort.
Additionally, low viscosity eye drops often come with no preservatives in multi-dose containers, making these options more convenient and safer for frequent use.
Further, the low viscosity formulation's compatibility with contact lenses and decreased chance of residue buildup broadens their appeal.
Thus, the low viscosity segment continues to dominate the market as it meets the needs of a wide consumer base seeking quick, easy, and well-accepted dry eye relief.
Based on the distribution channel, the global OTC dry eye drops market is categorized into retail pharmacies, online pharmacies, and other distribution channels. The retail pharmacies segment dominated the market in 2024 and is expected to reach USD 1.7 billion by 2034.
Retail pharmacies serve as a convenient and widespread distribution channel for OTC dry eye drops. Their ease of access makes these products a preferred option for patients seeking prompt treatment for dry eye discomfort.
In contrast to treatments that require a prescription, OTC modes of treatment allow patients to take charge of their personal healthcare without the necessity of doctor appointments or medical consultations. This self-care behavior is more prevalent in regions where awareness of dry eye disease is rising, and patients are increasingly opting for over-the-counter remedies to avoid the cost and time associated with doctor appointments. Retail pharmacies have embraced this trend by providing a wide range of OTC dry eye drops to meet diverse consumer demands.
Retail pharmacies also benefit from established partnerships with drug manufacturing companies and distributors, hence enabling them to offer a diversity of brands and types of OTC dry eye drops.
Looking for region specific data?
The North America OTC dry eye drops market dominated the global market with a market share of 37.4% in 2024.
The U.S. market was valued at USD 514.7 million and USD 536.6 million in 2021 and 2022, respectively. The market size reached USD 591.1 million in 2024, growing from USD 561.8 million in 2023.
The U.S. holds a dominant position in the market owing to its advanced healthcare system, high acceptance of OTC products, and increasing prevalence of dry eye syndrome.
The widespread use of digital devices has led to increased screen time, leading to dry eye symptoms. This trend is particularly notable in the U.S., where digital device usage is prevalent, thereby boosting the demand for OTC dry eye solutions.
For instance, as per Statista, Americans spend an average of 7+ hours per day on screens. Prolonged screen exposure reduces blinking frequency, exacerbating dry eye symptoms.
In addition, market growth is aided by strong distribution networks and presence of leading pharmaceutical and healthcare companies, such as Bausch + Lomb and Alcon in the country, which further boosts market growth.
Europe OTC dry eye drops market accounted for USD 464.2 million in 2024 and is anticipated to show lucrative growth over the forecast period.
Europe holds a significant share of the market due to its strong healthcare infrastructure, high awareness of ocular health, and an increasing aging population susceptible to dry eye disease.
For example, the European Commission reported that as of 2024, approximately 21.6% of the population in Europe was aged 65 years or older.
Along with the demographic features, Europe's OTC market for dry eye drops is supported by the presence of many well-known pharmaceutical and healthcare companies. These companies have been able to develop new formulations and delivery systems to address the needs of consumers.
Furthermore, enhanced access through e-commerce, as well as the expansion of retail pharmacy chains throughout Europe, have improved availability even in rural regions, further strengthening the market growth.
Germany OTC dry eye drops market is anticipated to witness considerable growth over the analysis period.
In 2023, 40-59-year-olds made up the largest age group in Germany, at almost 23 million people. Further, the share of the German population aged 65 years and older was 22.3% in the same year.
This aging population means more people suffer from dry eye syndrome, resulting in greater demand for over-the-counter eye care products.
Moreover, greater digital device usage has led to a surge in people suffering from strained eyes, which further bolsters the demand for dry eye symptom relief, thus increasing consumption of OTC dry eye drops.
The market is also fueled by Germany's high degree of trust in OTC medicines, combined with the country's sophisticated pharmaceutical distribution systems.
The Asia Pacific OTC dry eye drops market is anticipated to witness significant growth over the analysis timeframe.
The growth of digital devices, especially in younger generations, has exacerbated the problem of dry eye syndrome.
Increased screen time due to work, education, and leisure activities has created an increased demand for OTC dry eye solutions.
Moreover, the rapid growth in the aging population in the region, who suffer from age-related eye problems, further solidifies the market for OTC dry eye drops.
For instance, in Asia and the Pacific, the number of older people is projected to more than double, from 630 million in 2020 to about 1.3 billion by 2050.
Further, emerging markets like India, China, and the rest of Southeast Asia are also driving economic growth.
With rising income levels, modern retail and e-commerce make healthcare services more accessible than before, resulting in easier access to OTC eye care products, thus boosting the regional market growth.
China OTC dry eye drops market is predicted to grow significantly over the forecast period.
Due to a combination of factors, including rising awareness, increasing screen time, and greater access to self-medication options, China is anticipated to witness significant growth in the Asia Pacific market.
Symptoms of dry eye disease are becoming more prevalent in the country, especially in urban and working populations, due to the country's rapid digital transformation and the widespread use of smartphones, computers, and other digital devices.
For example, in China, it is estimated that 21–30% of people over 40 years of age have dry eye, and this prevalence is higher than reported in the U.S. or Europe.
Additionally, easy access to OTC dry eye drops through retail pharmacies and online platforms has accelerated market growth.
Brazil is experiencing significant growth in the Latin America OTC dry eye drops market due to the increasing demand for OTC solutions to manage dry eye symptoms.
Brazil is anticipated to witness high growth in the Latin America market owing to demographic, environmental, and healthcare access factors.
The most significant driver is the constantly increasing elderly population, as older individuals are more likely to develop dry eyes because of decreased tear production.
Furthermore, increased screen time due to high usage of digital devices has worsened dry eye symptoms for people of all ages, creating more demand for OTC solutions.
Also, increased pollution and dust further exacerbate the symptoms of dry eye syndrome, thus boosting the adoption rates of OTC dry eye drops.
Saudi Arabia OTC dry eye drops market is poised to witness substantial growth in Middle East and Africa market during the forecast period.
Saudi Arabia is witnessing rapid growth in the Middle East and Africa market because of the increasing awareness of eye health and the growing prevalence of dry eye disease.
The country's dry climate along with the dust and air pollution causes dry eye symptoms to be more common among the population.
Furthermore, rapid expansion of retail pharmacies and e-commerce stores is improving access to OTC dry eye solutions, thereby fostering market growth.
OTC Dry Eye Drops Market Share
The global market is characterized by the presence of several players including large multinational corporations, local and regional manufacturers, and start-ups. Top 5 players such as Alcon, Bausch Health Companies, AbbVie, Prestige Consumer Healthcare, and Rohto Pharmaceutical hold ~45% of the global market. These key market players are using strategic growth initiatives such as partnerships and acquisitions, new product launches, and geographic expansion to enhance their market presence and gain competitive edge.
These players focus on new innovations and develop eye care products centered on customer needs to increase their share in the rapidly growing industry. For example, continuous investment in R&D for the development of novel preservative-free and multi-dose formulations has become a prominent trend among these companies.
OTC Dry Eye Drops Market Companies
Few of the prominent players operating in the OTC dry eye drops industry include:
AbbVie
Alcon
Bausch Health Companies
Jadran-Galenski Laboratorij
Medicom Healthcare
NovaBay Pharmaceuticals
OASIS
Prestige Consumer Healthcare
Rohto Pharmaceutical
Santen Pharmaceutical
Similasan Corporation
Scope Eyecare
Thea Pharmaceuticals
URSAPHARM Arzneimittel
Alcon maintains a robust presence in the market, focusing on offering advanced, patient-friendly solutions to address dry eye symptoms. The company's popular Systane line, which includes multiple preservative-free options, caters to diverse consumer preferences and needs. Alcon's innovation-driven approach is evident in its continued investment in multi-dose delivery systems. For example, in August 2022, Alcon launched Systane Complete Preservative-Free in Canada, a multi-dose, all-in-one solution targeting dry eye relief, which significantly strengthened its OTC offering in the Canadian market.
Bausch Health Companies, operating through its globally recognized subsidiary Bausch + Lomb, holds a significant position in the market. The company continues to expand its footprint through a combination of innovative product development and strategic acquisitions.
OTC Dry Eye Drops Industry News
In February 2025, Alcon launched SYSTANE PRO Preservative-Free in the U.S., featuring its longest-lasting formula for dry eye relief. This launch strengthens Alcon's position in the market with an advanced, preservative-free solution.
In July 2024, AbbVie launched Refresh Tears PF and Refresh Relieva PF Xtra, both preservative-free eye drops. These products aim to offer extended relief for dry eye symptoms, expanding AbbVie's OTC eye care portfolio.
In May 2024, NovaBay Pharmaceuticals launched new Avenova product bundles for individualized dry eye relief. The bundles address multifactorial symptoms with a combination of lid hygiene, hydration, and heat therapy. This initiative reflects rising interest in tailored OTC solutions for dry eye management in the U.S.
In July 2023, Bausch + Lomb, a subsidiary of Bausch Health Companies, completed the acquisition of the Blink line of OTC eye drops from Johnson & Johnson, expanding its product portfolio in the market.
The OTC dry eye drops market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:
to Buy Section of this Report
Market, By Product Type
Preservative
Preservative-free
Market, By Type
Branded
Generics
Market, By Viscosity
Low viscosity
High viscosity
Market, By Distribution Channel
Online pharmacies
Retail pharmacies
Other distribution channels
The above information is provided for the following regions and countries:
North America
U.S.
Canada
Europe
Germany
UK
France
Spain
Italy
Netherlands
Asia Pacific
China
Japan
India
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa
Saudi Arabia
South Africa
UAE
Author: Mariam Faizullabhoy, Gauri Wani
Frequently Asked Question(FAQ) :
Who are some of the prominent players in the OTC dry eye drops market?+